降低58.4斤！替尔泊肽减重效果超越胃部切除手术

Core Insights - Tirzepatide has shown significant weight loss results, with patients losing an average of 29.2 kg over 84 weeks [2][8] - The drug activates GIP and GLP-1 receptors, leading to reduced caloric intake, appetite regulation, and improved fat metabolism [2] Study Results - The SURMOUNT-3 study demonstrated that patients treated with tirzepatide lost an average of 21.1% of their body weight after 72 weeks, and 26.6% (29.2 kg) after 84 weeks, compared to only 3.8% (4.1 kg) in the placebo group [8] - In the SURMOUNT-CN study, after 52 weeks, the 10 mg and 15 mg groups had weight reductions of 14.4% and 19.9%, respectively, significantly outperforming the placebo group [9] Safety Profile - The overall safety profile of tirzepatide in recent studies is consistent with previous research, with gastrointestinal issues being the most common side effects, mostly mild to moderate [10] Comparison with Surgical Options - Tirzepatide's weight loss efficacy is comparable to that of bariatric surgery, which has an average weight loss rate of 25.2% after one year [11]